Sleep Medicine

Dynamic OSA status in men predicts MACCE despite apparent remission

In this SHHS cohort, 2,653 participants had two PSGs about five years apart, with OSA defined as AHI ≥15/h. About 20% of initially non-OSA participants developed OSA, while roughly one-third with OSA reverted to non-OSA. In men, transition to OSA, remission from OSA, or stable OSA all increased MACCE risk versus stable non-OSA. AHI gain predicted higher MACCE and mortality in men, whereas no significant associations were seen in women. 1

Semaglutide reduces new-onset OSA and cardiorenal events in obesity

This TriNetX study compared semaglutide users with matched controls in obesity cohorts with and without baseline OSA. In obesity without OSA, semaglutide was associated with lower incident OSA (HR 0.62; 95% CI 0.60–0.63). In obesity with OSA, semaglutide reduced a composite of mortality, MACE, and MAKE (HR 0.72; 95% CI 0.66–0.78). All-cause mortality, MACE, and MAKE were each significantly lower, supporting semaglutide as disease-modifying in obesity-related OSA. 2

COPD–OSA overlap on domiciliary NIV has lower mortality

This French national cohort included 54,545 COPD patients ≥40 years initiated on home NIV for hypercapnic respiratory failure. Multistate models compared transitions between stable, severe exacerbation, and death for overlap syndrome versus COPD without OSA. Overlap patients had lower probabilities of death from both stable and severe exacerbation states than COPD-only patients. They were more likely to recover from severe exacerbations, and overall mortality after NIV initiation was 33% lower in overlap syndrome. 3